Epstein Secrets

or police restructuring and racial justice." Johnson: Intent On Columbus Day Was Mischaracterized. The Federalist (7/7, Justice, 126K) reports Sen. Ron Johnson (R-WI) "pulled back from his proposal" with Sen. James Lankford (R-OK) "last week to yank Columbus Day from the federal holiday calendar in exchang

shown to be effective in clinical trials." CNN (7/7, Cohen, Bonifield, 83.16M) reports on its website that Novavax CEO/President Stanley Erck "said Novavax's vaccine could be on the market by the first quarter of next year." The Hill (7/7, Budryk, 2.98M) reports that "the award will also cover a large-

rnment To Pay $1.6B For Rush Vaccine Development. The CBS Evening NewsVi (7/7, story 3, 1:40, O'Donnell, 4.24M) reported, "Maryland biotech company Novavax is in the hunt for a coronavirus vaccine, and getting a major dose of funding from the government's Operation Warp Speed program." The New York lime

el Flynn, two Senate-panel chairmen said Monday." Taylor "authored an op-ed vowing resistance to President Trump." Sens. Charles Grassley (R-IA) and Ron Johnson (R- WI) "cited a newly-declassified May 2017 Justice Department document summarizing the FBI's efforts in its EFTA00137303 Russian collusion probe

ted by more than $10 billion in U.S taxpayer dollars. The government is also supporting an experimental vaccine from Sanofi/GSK and one from startup Novavax, which are expected to begin large trials in the U.S. in the coming weeks. Merck, which has received far less funding, is a few months further behi

l Flynn, two Senate-panel chairmen said Monday." Taylor "authored an op-ed vowing resistance to President Trump." Sens. Charles Grassley (R-IA) and Ron Johnson (R-WI) "cited a newly-declassified May 2017 Justice Department document summarizing the FBI's efforts in its Russian collusion probe." The document

ed by more than $10 billion in U.S taxpayer dollars. The government is also supporting an experimental vaccine from Sanofi/GSK and one from startup Novavax, which are expected to begin large trials in the U.S. in the coming weeks. Merck, which has received far less funding, is a few months further behin